Disulfiram/Cu Kills and Sensitizes BRAF -Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways

, the most common genetic alteration, has become a major therapeutic target in thyroid cancer. Vemurafenib (PLX4032), a specific inhibitor of kinase, exhibits antitumor activity in patients with -mutated thyroid cancer. However, the clinical benefit of PLX4032 is often limited by short-term response...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2023-02, Vol.24 (4), p.3418
Hauptverfasser:	Xie, Jingyi, Liu, Juan, Zhao, Man, Li, Xinru, Wang, Yubo, Zhao, Yuelei, Cao, Hongxin, Ji, Meiju, Chen, Mingwei, Hou, Peng
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase AKT protein Antitumor activity Apoptosis Aversion Cell growth Cell Line, Tumor Cell proliferation Disulfiram Disulfiram - therapeutic use Drug dosages Enzyme inhibitors Extracellular signal-regulated kinase Feedback Flow cytometry Humans Indoles - pharmacology Iodine Kinases MAP kinase Mutants Mutation Phosphatidylinositol 3-Kinases - metabolism Phosphorylation Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins c-akt - metabolism Reactive Oxygen Species Sulfonamides - pharmacology Therapeutic targets Thyroid cancer Thyroid Neoplasms - pathology Tumorigenesis Vemurafenib - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!